Compare Amgen, Inc. (AMGN) vs Vanguard S&P 500 ETF (VOO) Price & Performance

Amgen, Inc.Trade

Vanguard S&P 500 ETFTrade

Price performance (Past 24H)

Key statistics

Amgen, Inc. vs Vanguard S&P 500 ETF — how do they compare? Amgen, Inc. trades at $412.77 (market cap $224.14B), while Vanguard S&P 500 ETF trades at $709.93. The key difference: Amgen, Inc. pays a 2.43% dividend while Vanguard S&P 500 ETF pays none. Which is the better fit depends on your goals.

	AMGN	VOO
Market Cap	$224.14B	—
Sector	Health	Broad Market / Factor
52-Week High	$417.20	$710.71
52-Week Low	$271.18	$580.93
Enterprise Value	$267.45B	—
Dividend Yield	2.43%	—

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

AMGN

BioCryst hits profitability with strong Q2 revenue, sparking takeover interest in rare disease biotech.24/7 Wall Street · 1 day agoBullish View details →

VOO

Fidelity's zero-fee fund challenges Vanguard's S&P 500 ETF but offers limited gains for taxable accounts.24/7 Wall Street · 1 day agoNeutral Vanguard High Dividend Yield ETF lags S&P 500 by $141K over 10 years despite dividends.24/7 Wall Street · 1 day agoBearish Vanguard's S&P 500 ETF (VOO) offers cheaper, more flexible access than the mutual fund VFIAX.24/7 Wall Street · 2 days agoBullish View details →

About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

About Vanguard S&P 500 ETF

VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.